ArriVent BioPharma (AVBP) Payables (2023 - 2026)

ArriVent BioPharma has disclosed Payables across 4 years of filings, most recently posting $8.7 million for Q1 2026.

• Payables for Q1 2026 came in at $8.7 million, up 99.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.7 million (up 99.98% YoY), and the FY2025 annual result was $5.9 million, up 56.9% from the prior year.
• Payables came in at $8.7 million for Q1 2026 at ArriVent BioPharma, up from $5.9 million in the prior quarter.
• In the past five years, Payables ranged from a high of $8.7 million in Q1 2026 to a low of $3.8 million in Q4 2024.
• The 4-year median for Payables is $4.4 million (2023), against an average of $5.0 million.
• Across the five-year window, Payables slipped 16.55% in 2024 and jumped 99.98% in 2026, its largest moves.
• ArriVent BioPharma's Payables stood at $4.5 million in 2023, then fell by 16.55% to $3.8 million in 2024, then surged by 56.9% to $5.9 million in 2025, then surged by 47.07% to $8.7 million in 2026.
• The last three Payables figures came in at $8.7 million (Q1 2026), $5.9 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.